Moderna (MRNA) Common Equity (2017 - 2026)

Moderna (MRNA) has 10 years of Common Equity data on file, last reported at $7.4 billion in Q1 2026.

• On a quarterly basis, Common Equity fell 26.41% year-over-year to $7.4 billion in Q1 2026; TTM through Mar 2026 was $7.4 billion, a 26.41% decrease from a year earlier, with the FY2025 full-year figure at $8.6 billion, down 20.65% from the prior year.
• Common Equity for Q1 2026 stood at $7.4 billion, down from $8.6 billion in the prior quarter.
• Over the last five years, Common Equity for MRNA reached as high as $19.1 billion in Q4 2022 and fell as low as $7.4 billion in Q1 2026.
• Historically, Common Equity has averaged $13.4 billion across 5 years, with a median of $12.8 billion in 2024.
• Across the five-year window, Common Equity surged 344.89% in 2022 and plunged 32.05% in 2024, its largest moves.
• Year by year, Common Equity stood at $19.1 billion in 2022, then fell by 27.55% to $13.9 billion in 2023, then declined by 21.32% to $10.9 billion in 2024, then retreated by 20.65% to $8.6 billion in 2025, then declined by 14.36% to $7.4 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $7.4 billion in Q1 2026, $8.6 billion in Q4 2025, and $9.3 billion in Q3 2025.